C12N 2750/14071
Demonstrated in vivo effect
C12N2750/14071 (Demonstrated in vivo effect) appears on 22 US grants and 38 published applications in this corpus.
Search patents in C12N- Granted patents
- 22
- Published applications
- 38
- Assignees
- 28
- Inventors
- 57
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 2 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 2 | 1 |
| 2013 | 1 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 2 |
| 2016 | 0 | 2 |
| 2017 | 1 | 2 |
| 2018 | 1 | 2 |
| 2019 | 2 | 1 |
| 2020 | 2 | 4 |
| 2021 | 1 | 4 |
| 2022 | 3 | 5 |
| 2023 | 2 | 5 |
| 2024 | 1 | 2 |
| 2025 | 3 | 3 |
| 2026 | 2 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency29 Sep 2026US 12,747,429 B2The Trustees of the University of Pennsylvania
- Gene therapy for retinal disease9 Jun 2026US 12,649,007 B2Oxford University Innovation Limited
- Clinical parameters by expression of factor VIII16 Dec 2025US 12,497,632 B2Sangamo Therapeutics, Inc.
- Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy5 Aug 2025US 12,377,170 B2Research Institute At Nationwide Children's Hospital
- Methods of vaccine administration6 May 2025US 12,290,559 B2Zoetis Services LLC
- Adeno-associated virus vector delivery of b-sarcoglycan and the treatment of muscular dystrophy14 May 2026US 2026/0131032 A1Research Institute At Nationwide Children's Hospital
- Adeno-associated virus compositions for targeted gene therapy5 Jun 2025US 2025/0179441 A1California Institute of Technology
- Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to energy failure3 Apr 2025US 2025/0109407 A1Assistance Publique-HôPitaux De Paris (Aphp)
- Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure3 Apr 2025US 2025/0109408 A1
- Adeno-associated virus compositions for targeted gene therapy28 Mar 2024US 2024/0101969 A9California Institute of Technology
Most cited
By later US patents
- Methods and pharmaceutical compositions for the treatment of cardiomyopathy due to friedreich ataxia26US 9,066,966 B2Assistance Publique-HôPitaux De Paris (Aphp) · 2015
- Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy due to Friedreich ataxia13US 10,337,027 B2Aphp (Assistance Publique - HôPitaux De Paris) · 2019
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency13US 9,890,365 B2The Trustees of the University of Pennsylvania · 2018
- Adeno-associated virus compositions for targeted gene therapy11US 11,149,256 B2California Institute of Technology · 2021
- Compositions useful in treatment of ornithine transcarbamylase (OTC) deficiency10US 10,167,454 B2The Trustees of the University of Pennsylvania · 2019